Zusammenfassung
Krebspatienten benötigen häufig supportive Maßnahmen aufgrund der Auswirkungen des Tumors oder der Tumortherapie auf den Organismus. Bereits die Diagnose einer bösartigen Erkrankung bedeutet für den Patienten eine erhebliche Streßsituation, so daß die Unterstützung durch einen auf diesem Gebiet erfahrenen Arzt und/oder Psychoonkologen benötigt wird. Bei einer fortgeschrittenen Tumorerkrankung hat die Schmerztherapie eine zentrale Bedeutung, um dem Kranken seine Lebensqualität soweit wie möglich zu erhalten. Weitere supportive Maßnahmen sind die Substitution von Blut und Blutprodukten und die Ernährung.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Balkwill F Burke F, Talbot D et al. (1987) Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2: 1229–1232
Berdel WE, Oberberg D, Reufi B, Thiel E (1991) Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 63: 5–8
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–340
Clamon GH, Feld R, Evans WK et al. (1985) Effect of adjuvant central IV hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 69: 167–177
Dale DC, Guerry D, Wewerka IV Jr, Bull JM, Chusid MJ (1979) Chronic neutropenia. Medicine 58: 128–144
Deisseroth A, Wallerstein R (1989) Use of blood and blood products. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 2045–2059
DeWys WD, Begg C, Lavin PT et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491–497
Doenicke A (1987) Medikamentöse Schmerztherapie beim inkurablen Prostatakarzinom. Aktuel Urol 18: 210–214
Drew JW, Winston G, Gale RP (1982) Therapeutic granulocyte transfusions for documented infections. Ann Intern Med 97: 509–515
Evans WK, Nixon DW, Daly JM et al. (1987) A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 5: 113–124
Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern cooperative oncology group study. J Clin Oncol 4: 702–709
Gabrilove JL, Jakubowski A, Scher H et al. (1988) Effect of granulocyte colonystimulating factor on neutropenia and associated morbitity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414–1422
Gaydos LA, Freireich EJ, Mantel N (1962) The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266: 905–909
Harker LA, Slichter SJ (1972) The bleeding time as screening test for evaluation of platelet function. N Engl J Med 287: 155–159
Herrmann F Ganser A, Lindemann A, Schulz G, Lübbert M, Hoelzer D, Mertelsmann R (1990) Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administration. J Biol Resp Mod 9: 475–479
Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R (1982) The effect of granulocyte transfusion upon the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 96: 149–152
Hitomi K, Fujita K, Sasaki R et al. (1988) Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochem Biophys Res Comm 154: 902–909
Hollingshead LM, Goa KL (1991) Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42: 300–330
Hughes WT Armstrong D, Bodey GP et al. (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396
Hughes WT, Armstrong D, Bodey GP et al. (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396
Issel BE Valdivieso M, Zaren H (1978) Protection against chemotherapy toxicity by i.v. hyperalimentation. Cancer Treat Rep 59: 437
Jordan WM, Valdivieso M, Frankman C (1981) Treatment of advanced adenocarcinoma of the lung with ftorofur, doxorubicin, cyclophosphamide, and cis-platinum and intensive iv. hyperalimentation. Cancer Treat Rep 64: 197
Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with mulitple myeloma. N Engl J Med 322: 1693–1699
Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Guttermann JU (1990) Escalated therapy for refractory urothelial tumors: methotrexate-vinblastinedoxorubicin-cisplatin plus unglycosylated recombinant human granulocytemacrophage colony-stimulating factor. J Natl Cancer Inst 82: 667–672
Meryman HT (1989) Transfusion-induced alloimmunization and immunosuppression and the effects of leukozyte depletion. Transfusion Med Rev 3: 180–193
Metcalf D (1990) The colony stimulating factors. Discovery, development, and clinical applications. Cancer 65: 2185–2195
Müller JM, Brenner U, Dienst C, Pichlmaier H (1982) Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1: 68–71
Mundt D, Berger MR, Bode G (1992) Effect of recombinant human erythropoietin in the growth of human tumor cell lines in vitro. Drug Res 42: 92–95
Okuno Y, Takahashi T, Suzuki A et al. (1990) Expression of the erythropoeitin receptor on a human myeloma cell line. Biochem Biophys Res Comm 170: 1128–1134
Pecherstorfer M, Schmoranzer F, Vesely M, Fortelny A, Baumgartner G (1990) Erythropoietin beim multiplen Myelom. Dtsch Med Wochenschr 115: 1096–1099
Pizzo PA, Meyers J (1989) Infections in the cancer patient. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 2088–2133
Samuels ML, Selig R, Ogden S (1981) IV hyperalimentation and chemotherapy for stage III testicular cancer: a randomized study. Cancer Treat Rep 65: 615
Serrou B, Cupissol D, Plagne R (1981) Parenteral intravenous nutrition (PNH) as an adjunct to chemotherapie in small cell anaplastic lung carcinoma. Cancer Treat Rep [Suppl 5] 65: 151
Shike M, Brennan MF (1989) Supportive care of the cancer patient. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds), Cancer principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 2029–2044
Walker RH (1987) Special report: transfusion risks. Am J Clin Pathol 88: 374–378
Warren S (1932) The immediate causes of death in cancer. Am J Med Sci 184: 610
Weissmann DE, Dahl JL (1990) Attitudes about cancer pain: a survey of Wisconsin’s first year medical students. J Pain Symptom Management 5: 345–349
World Health Organization (1986) Cancer pain relief. Office of Publications, WHO, Geneva 1986
Zimmermann M (1981) Physiologische Mechanismen von Schmerz and Schmerztherapie. Triangle 20: 7–18
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wirth, M. (1994). Supportive Maßnahmen beim Krebspatienten. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22585-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-662-22585-1_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22586-8
Online ISBN: 978-3-662-22585-1
eBook Packages: Springer Book Archive